Page last updated: 2024-09-04

atrasentan and Vomiting

atrasentan has been researched along with Vomiting in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Groenewegen, G; Kronemeijer, RH; Los, M; van der Mijn, KJ; Voest, EE; Witteveen, PO	1

Trials

1 trial(s) available for atrasentan and Vomiting

Article	Year
Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:11 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Pyrrolidines; Survival Analysis; Treatment Outcome; Vomiting	2010

Article

Year

Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.

Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:11

Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Pyrrolidines; Survival Analysis; Treatment Outcome; Vomiting

2010